机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China神经内科[2]Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland[3]Department of Neurosurgery, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland[4]School of Pharmacy, University of Eastern Finland, Kuopio, Finland[5]School of Life Sciences, University of Warwick, Coventry, United Kingdom[6]Neurocenter, Kuopio University Hospital, Kuopio, Finland
第一作者机构：[1]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China[2]Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland
通讯作者：
通讯机构：[*1]Institute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1C (PO Box 1627), 70211 Kuopio, Finland.[2]Institute of Clinical Medicine-Neurology, University of Eastern Finland, Kuopio, Finland[6]Neurocenter, Kuopio University Hospital, Kuopio, Finland
推荐引用方式(GB/T 7714)：
Li-li Cui,Dominika Golubczyk,Anna-Maija Tolppanen,et al.Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy?[J].Annals of neurology.2019,86(1):5-16.doi:10.1002/ana.25493.
APA：
Li-li Cui,Dominika Golubczyk,Anna-Maija Tolppanen,Johannes Boltze&Jukka Jolkkonen.(2019).Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy?.Annals of neurology,86,(1)
MLA：
Li-li Cui,et al."Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy?".Annals of neurology 86..1(2019):5-16
医学